Author

Christopher O’Sullivan

Observed names: C O'Sullivan, C. O'Sullivan, C. O’Sullivan, Christopher O'Sullivan

Institutions: Prince Charles Hospital, Gilead Sciences (United States)

Observed institutions: Brigham and Women's Hospital, Harvard University, Freeman Hospital, Geron (United States), Prince Charles Hospital, Gilead Sciences (United States)

OpenAlex ID: A5110103518

Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer

2015 · Derek C. Marshall, Susan K. Lyman, et al. · PLoS ONE · 209

Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung.

1994 · S Yei, N Mittereder, et al. · PubMed · 189

Endoscopic necrosectomy as primary therapy in the management of infected pancreatic necrosis

2006 · R. Charnley, R. Lochan, et al. · Endoscopy · 176

Non-Catalytic Site HIV-1 Integrase Inhibitors Disrupt Core Maturation and Induce a Reverse Transcription Block in Target Cells

2013 · Mini Balakrishnan, Stephen R. Yant, et al. · PLoS ONE · 130

Is Circulating Endotoxin the Trigger for the Systemic Inflammatory Response Syndrome Seen After Injury?

1997 · John L. Kelly, Christopher O'Sullivan, et al. · Annals of Surgery · 85

Characterisation of neurological injury in the modern era of transcatheter aortic valve implantation (TAVI)

2015 · J. Fanning, D. Walters, et al. · Heart Lung and Circulation

Abstract A56: The telomerase inhibitor imetelstat exhibits antitumor and anticancer stem cell effects through perturbation of casein kinase-2 signaling.

2011 · Ryan T. Nitta, Christopher O'Sullivan, et al. · Molecular Cancer Therapeutics

Works count: 7

Citation count: 789

H-index: 5

I10-index: 5